Clinical trials
Treating people with cancer in clinical trials
CellCentric is focused on developing inobrodib to transform cancer treatment outcomes for maximum benefit to patients. Inobrodib has a defined spectrum of potential applications due to its mechanism of action. Different cancer indications can be targeted by inobrodib as a monotherapy or in combination with existing standard of care drugs.
Inobrodib was the first orally available drug of its kind and the first inhibitor of p300/CBP to be evaluated in clinical trials. For hematological malignancy applications in particular, oral administration is a key advantage.
Current clinical trials
Inobrodib has been evaluated in over 500 patients to date across various tumor types.
Multiple Myeloma Clinical Trials
Inobrodib is currently being evaluated in combination with pomalidomide and dexamethasone (InoPd) in multiple myeloma patients in a Phase 2 trial (NCT07096778) as well as in a haematological malignancies trial with other drug combinations and indications (NCT04068597).
Note for Patients
Potential eligibility for enrollment in an inobrodib clinical trial will be made by oncologists at participating clinical trial sites, and not by CellCentric. Any advice on clinical study options should come from your doctor.
Latest press releases
